Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206979 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL175956 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29438477 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29793991 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29423449 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL24899366 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL3309050 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL2367138 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL31370735 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL25253964 | 0.88 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-10-16 | — | — | US | disclosed |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | IRM LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8808703-B2 | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-08-19 | — | — | US | disclosed |
| EP-2719395-A1 | Adsorption of immunopotentiators to insoluble metal salts | Novartis AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2480253-B1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-03-14 | — | — | US | disclosed |
| EP-2549990-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-01-30 | — | — | EP | disclosed |
| EP-2480253-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| WO-2012031140-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011119759-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | MDM4 3600/4885TP53 180/4885MDM2 4797/4885 |
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | TLR2, TLR1, TLR3 | MDM4 4594/4885TP53 1009/4885MDM2 1520/4885 |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | TLR2, TLR4, TLR3 | MDM4 3173/4885TP53 1326/4885MDM2 1856/4885 |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | MDM4 319/4885TP53 191/4885MDM2 1287/4885 |
| US-10098949-B2 | Adsorption of immunopotentiators to insoluble metal salts | CD69, NFATC1, CD209 | MDM4 336/4885TP53 169/4885MDM2 1111/4885 |
| US-20120177681-A1 | Formulation of immunopotentiators | CD69, CD4, ICOS | MDM4 474/4885TP53 135/4885MDM2 970/4885 |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | MDM4 319/4885TP53 191/4885MDM2 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.